CD274 and non-small cell lung carcinoma: Advanced NSCLC patients were randomly assigned to receive nivolumab plus ipilimumab, nivolumab alone (only for PD-L1 > 1%), nivolumab plus chemotherapy (only for PD-L1 < 1%), or chemotherapy alone.